CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer

Lancet Oncol. 2024 Jul;25(7):e282. doi: 10.1016/S1470-2045(24)00261-4.

Authors

Anna-Maria Lazaratos¹, Kevin Petrecca², Marie-Christine Guiot², Katarzyna J Jerzak³, Matthew Dankner⁴

Affiliations

¹ Rosalind and Morris Goodman Cancer Research Institute, McGill University, Montreal, QC H3A 1A3, Canada.
² Montreal Neurological Institute-Hospital, McGill University, Montreal, QC H3A 1A3, Canada.
³ Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
⁴ Rosalind and Morris Goodman Cancer Research Institute, McGill University, Montreal, QC H3A 1A3, Canada. Electronic address: [email protected].

PMID: 38936381
DOI: 10.1016/S1470-2045(24)00261-4

No abstract available

Publication types

News
Letter

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use
Brain Neoplasms / drug therapy
Brain Neoplasms / genetics
Camptothecin* / analogs & derivatives
Camptothecin* / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Non-Small-Cell Lung* / pathology
Female
Humans
Immunoconjugates / therapeutic use
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Lung Neoplasms* / pathology
Receptor, ErbB-2* / metabolism
Trastuzumab* / therapeutic use

Substances

Trastuzumab
Receptor, ErbB-2
Camptothecin
trastuzumab deruxtecan
ERBB2 protein, human
Immunoconjugates
Antineoplastic Agents, Immunological